Mr. Soni is CFO of Alnylam Pharmaceuticals, Inc where he manages global finance, tax, treasury, procurement, investor relations and corporate communications. He is currently board member at Pulse Biosciences and Arena Pharmaceuticals, Inc. He is former CFO of ARIAD Pharmaceuticals, Inc. He played a vital role in the acquisition of ARIAD by Takeda for over $5.2 billion. He also played important role in strategic review and executing a turnaround for ARIAD. ARIAD focused on discovering, developing and commercializing precision therapies for patients with rare cancers. Mr. Soni managed Finance & Accounting, Investor Relations, Corporate communications, IT and Facilities department at ARIAD.
Before joining Ariad Pharmaceuticals as CFO, Mr. Soni worked at Pharmacyclics from 2012 to 2015 in various roles in Finance & Accounting, Business Development, Human Resources and Commercial operations. Mr. Soni played a vital role in Pharmacyclics' acquisition by Abbvie for $21 billion. Most recently he worked as Chief Financial Officer and Treasurer at Pharmacyclics where he played a key role in building the company from clinical company to a fully viable commercial company. Mr. Soni was responsible for all Finance & Accounting, Aggregate Spend, Procurement, Business Development, IT and HR functions in the Company. Prior to that, Mr. Soni worked at PricewaterhouseCoopers (PwC) for more than 10 years. Most recently, he was in the Life Science and Venture Capital Group of the PwC San Jose office providing assurance services to various public and privately held pharmaceutical and biotech companies.
He graduated from Hansraj College at Delhi University in India. He is a Certified Public Accountant, licensed in the state of California and Chartered Accountant from India.